• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

    1.970 +0.020 (+1.03%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Iovance Biotherapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    13 14 Next >
    Adaptimmune Plunges After Announcing Nasdaq Delisting Amidst Compliance Failures and Cost-Cutting Measures
    Adaptimmune Therapeutics plc (NASDAQ: ADAP) has sent shockwaves through the biotechnology sector with its announcement on October 20, 2025, of a voluntary delisting of its American Depositary Shares... 
    Via MarketMinute
    Topics Initial Public Offering Regulatory Compliance Workforce
    Turnstone Biologics: A $100 Dream Collides with a $0.34 Reality
    October 17, 2025 – In the volatile world of biotechnology, ambitious price targets often fuel investor speculation and market buzz. However, for Turnstone Biologics Corp. (NASDAQ: TSTN), the notion of... 
    Via MarketMinute
    Topics Intellectual Property Workforce
    Iovance Stock Rises 4% On Health Canada Approval For Cancer Immunotherapy: Retail Thinks ‘Patience Will Pay Off’
    Via Stocktwits
    Earnings Scheduled For August 7, 2025
     
    Via Benzinga
    Better Beaten-Down Stock: Iovance Biotherapeutics vs. Teladoc Health
    Is there a glimmer of hope for either of these underperforming healthcare companies? 
    Via The Motley Fool
    Is Iovance Biotherapeutics Stock Your Ticket to Becoming a Millionaire?
    Investors have certainly seen explosive gains from shares of biopharma companies in similar situations. 
    Via The Motley Fool
    Can This Beaten-Down Stock Bounce Back?
    This biotech company is innovative, but the market demands more than that. 
    Via The Motley Fool
    If You'd Invested $1,000 in IOVA 3 Years Ago, Here's How Much You'd Have Today
    The company hasn't been popular among investors since winning its first FDA approval more than a year ago. 
    Via The Motley Fool
    Why Iovance Biotherapeutics Stock Got Mashed on Monday
    The company announced a flotation of its common shares that is potentially quite dilutive. 
    Via The Motley Fool
    Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday
     
    Via Benzinga
    1 Beaten-Down Stock That Could Soar By 261%, According to Wall Street
    Time is running out for the company to mount a comeback. 
    Via The Motley Fool
    Why Iovance Biotherapeutics Stock Was Climbing Today
    One and a half years after getting the nod from the U.S. Food and Drug Administration, its Amtagvi moves forward in a neighboring country. 
    Via The Motley Fool
    Intel, Plymouth Industrial REIT, Premier And Other Big Stocks Moving Higher On Tuesday
     
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
     
    Via Benzinga
    Why Palo Alto Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
     
    Via Benzinga
    Curious about the stocks that are showing activity after the closing bell on Monday?
    As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
    Via Chartmill
    3 Stocks That Could Turn $1,000 Into $5,000 by 2030
    All three of these companies are entering a period of what could produce unparalleled top- and bottom-line growth. 
    Via The Motley Fool
    Why Iovance Biotherapeutics Stock Plummeted Today
    The company's top line nearly doubled. 
    Via The Motley Fool
    What 7 Analyst Ratings Have To Say About Iovance Biotherapeutics
     
    Via Benzinga
    Pinterest Posts Downbeat Q2 Earnings, Joins Twilio, Trade Desk And Other Big Stocks Moving Lower In Friday Pre-Market Session
     
    Via Benzinga
    Which stocks are moving before the opening bell on Friday?
    Before the opening bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
    Via Chartmill
    12 Health Care Stocks Moving In Friday's Pre-Market Session
     
    Via Benzinga
    Iovance Biotherapeutics Declines 29% In Premarket Trading: Here's What's Happening
    Iovance stock fell over 29% pre-market after Q2 results, despite reporting a strong revenue jump led by Amtagvi sales. 
    Via Benzinga
    Why Expedia Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
     
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's After-Market Session
     
    Via Benzinga
    Curious about the stocks that are showing activity after the closing bell on Thursday?
    Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
    Via Chartmill
    Iovance (IOVA) Q2 Revenue Jumps 93%
    Via The Motley Fool
    Topics Intellectual Property
    Is Iovance Biotherapeutics Stock Due for a Big Rally?
    The biotech stock has been picking up steam of late -- but will it last? 
    Via The Motley Fool
    This Beaten-Down Healthcare Stock Could Jump 720%, According to a Wall Street Analyst. Is It Time to Buy?
    Even the average price estimate for this stock suggests it can soar, but not everyone's convinced. 
    Via The Motley Fool
    12 Health Care Stocks Moving In Thursday's Intraday Session
     
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    13 14 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.